Drug intelligence / Profile preview

Hemastim P

Development stage: Unknown
Lead developer: Amega Biotech
Modality: Recombinant Proteins and Enzymes
Administration: Intravenous, Subcutaneous

Overview

Hemastim P is a biosimilar recombinant human erythropoietin (rhEPO) developed by Amega Biotech. It functions as an agonist of the erythropoietin receptor (EPOR), mimicking the action of endogenous erythropoietin to stimulate the proliferation and differentiation of erythroid progenitor cells in the bone marrow. This process, known as erythropoiesis, leads to an increase in red blood cell production and hemoglobin levels. Hemastim P is primarily indicated for the treatment of anemia associated with chronic kidney disease (CKD), oncology patients receiving chemotherapy, and other conditions characterized by insufficient red blood cell production.

Brand names: Hemastim P
Other names: ErythropoietinEPOrecombinant human erythropoietinrhEPO

Targets

Erythropoietin Receptor

Beyond the preview

Go deeper on Hemastim P.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Hemastim P.

Explore the full profile